Dr. Ronald F. van Vollenhoven

February 27, 2018 8:09 pm Published by

Ronald F. van Vollenhoven, MD, PhD, is Professor and Director of the Amsterdam Rheumatology and Immunology Center, Chief of the Department of Rheumatology and Clinical Immunology at the University of Amsterdam’s Faculty of Medicine and of the Department of Rheumatology at the University Medical Center.

After graduating from Leiden University, he pursued immunology research (Cornell Medical College, New York) and trained in Internal Medicine (State University of New York, Stony Brook) and Rheumatology (Stanford University, Palo Alto). Prior to 2016 he was the Fellowship Director at Stanford and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases at Karolinska University Hospital.

His research interests focus on the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases; he has been principal investigator in many clinical trials, including the SWEFOT trial. He is co-founder of the IRBIS (biologics in SLE) and CERERRA registries and of the NORD-STAR collaboration, and initiator of the Treat-to-Target-in-SLE initiative. He has published over 300 original papers, book chapters and reviews; edited Clinical Therapy Research in the Inflammatory Diseases (World Scientific Press, 2015); authored the monograph Biological Therapy of Rheumatoid Arthritis (Springer, 2015) and co-edited Dubois’ Lupus Erythematosus (Elsevier, 2014). He is Editor-in-Chief of Lupus Science & Medicine. He received the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology (2014). Outside his professional life he is an avid classical pianist.

Categorised in:

This post was written by admin